ADENOSCAN
LOE ApproachingNDAINTRAVENOUSSOLUTION
Approved
May 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADENOSCAN is an intravenous small-molecule diagnostic agent approved in 1995 used for cardiac stress testing in patients unable to exercise. The drug works as an adenosine receptor agonist to induce vasodilation and simulate cardiac stress, enabling myocardial perfusion imaging. It is indicated for patients undergoing pharmacologic stress testing to assess coronary artery disease.
LOE Approaching
With LOE approaching after 29 years on market, the brand team is likely operating in a managed-decline or transition mode with smaller dedicated headcount focused on retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)
Started Mar 2012
48 enrolled
Coronary Artery Disease
ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Started Apr 2004
787 enrolled
Coronary Artery Disease
ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Started Oct 2003
1,231 enrolled
Coronary Artery Disease
Career Relevance
Working on ADENOSCAN in a LOE-approaching phase means managing decline, defending market share, and executing cost-containment strategies rather than growth. This role is suitable for professionals seeking experience in portfolio management, mature product stewardship, or transition planning to higher-potential assets.
Worked on ADENOSCAN at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.